

July 18, 2018

Press Release

intellim Corporation completes all incorporation activities for intellim Malaysia Sdn. Bhd.

[Tokyo, Japan, July 13, 2018] intellim Corporation (President & CEO Masakuni Ukita, hereinafter known as “intellim”) announced that their wholly owned subsidiary, intellim Malaysia Sdn. Bhd. has completed all incorporation activities as of June 20, 2018. intellim Malaysia’s office is located strategically in Kuala Lumpur. This is the third subsidiary that intellim has opened on a global scale. intellim Malaysia will officially open their doors for operations on August 1, 2018.

1) Purpose of Incorporation

intellim, a full service CRO based in Tokyo, Japan, providing services to the pharmaceutical industry since 2005, has the vision of becoming Asia’s first Global Pharmaceutical Development Partner. In order to expand their provision of drug development services deeper into Asia, with their subsidiaries in Korea, Taiwan and now Malaysia, on March 23, 2018, intellim signed a Memorandum of Understanding and entered into strategic partnership with Clinical Research Malaysia (CEO Dr. Akhmal Yusof, hereinafter known as “CRM”), a government Non-Profit Organization with the purpose of advancing clinical research in Malaysia. intellim’s goal is to work with CRM, through intellim Malaysia expand clinical research and development into the region.

2) intellim Malaysia Sdn Bhd Details

Corporate Name: intellim Malaysia SDN. BHD. (Co No. 1284341-T)

Corporate Address: 27th Floor, Axiata Tower, Jalan Stesen Sentral 5
Kuala Lumpur Sentral 50470 Kuala Lumpur, Malaysia

Representative: President & CEO Masakuni Ukita

3) Primary Business Activity: Provide clinical R&D services in Malaysia to promote the development of novel pharmaceutical drugs and medical devices. Consisting of:

- 1) Establish a standardized clinical trial system that will result in high quality data which can be utilized for submission for marketing authorization in Japan.
- 2) Support for registration as well as marketing such pharmaceutical drugs and medical devices that have previously received marketing approval in other regions around the world.
- 3) Provide Artificial Intelligence (“AI”) call center platforms to medical institutions and the healthcare industry in Malaysia.
- 4) Implement high-quality training and education with the goal to further improve the quality of clinical trial conduct.

4) Contact Information

For more information regarding intellim's services in Malaysia, please contact the following:

Department: Malaysia Global Development Department

Tel: +81 3 5688-7232

Email: info@intellim.co.jp

For more information regarding the content of this press release please contact the following:

Email: pr@intellim.co.jp